Moderna, Inc. (MRNA) stock surged 5.15% in pre-market trading on Monday following the announcement of positive Phase 3 results for its experimental influenza vaccine. The biotechnology company reported that its mRNA-1010 vaccine demonstrated superior efficacy compared to licensed standard-dose seasonal flu shots in adults aged 50 years and older.
According to the late-stage study, Moderna's mRNA-1010 achieved a stringent superiority criterion with a relative vaccine efficacy (RVE) of 26.6% in the overall study population. The vaccine showed strong efficacy against various influenza strains, including A/H1N1, A/H3N2, and the B/Victoria lineages. Notably, in participants aged 65 years and older, mRNA-1010 demonstrated an RVE of 27.4%, highlighting its potential benefits for the elderly population.
The safety and tolerability profile of mRNA-1010 were consistent with previous studies, with most adverse reactions being mild. Moderna plans to present these findings at an upcoming medical conference and engage with regulators on filing submissions for mRNA-1010. This breakthrough in influenza vaccine development could potentially strengthen Moderna's position in the vaccine market, driving investor optimism and contributing to the significant pre-market stock price increase.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。